Zhao, S.; Zuo, J.; Mallillin, M.C., III; Tang, R.; Doschak, M.R.; Davies, N.M.; Löbenberg, R.
Improving Ex Vivo Nasal Mucosa Experimental Design for Drug Permeability Assessments: Correcting Mucosal Thickness Interference and Reevaluating Fluorescein Sodium as an Integrity Marker for Chemically Induced Mucosal Injury. Pharmaceuticals 2025, 18, 889.
https://doi.org/10.3390/ph18060889
AMA Style
Zhao S, Zuo J, Mallillin MC III, Tang R, Doschak MR, Davies NM, Löbenberg R.
Improving Ex Vivo Nasal Mucosa Experimental Design for Drug Permeability Assessments: Correcting Mucosal Thickness Interference and Reevaluating Fluorescein Sodium as an Integrity Marker for Chemically Induced Mucosal Injury. Pharmaceuticals. 2025; 18(6):889.
https://doi.org/10.3390/ph18060889
Chicago/Turabian Style
Zhao, Shengnan, Jieyu Zuo, Marlon C. Mallillin, III, Ruikun Tang, Michael R. Doschak, Neal M. Davies, and Raimar Löbenberg.
2025. "Improving Ex Vivo Nasal Mucosa Experimental Design for Drug Permeability Assessments: Correcting Mucosal Thickness Interference and Reevaluating Fluorescein Sodium as an Integrity Marker for Chemically Induced Mucosal Injury" Pharmaceuticals 18, no. 6: 889.
https://doi.org/10.3390/ph18060889
APA Style
Zhao, S., Zuo, J., Mallillin, M. C., III, Tang, R., Doschak, M. R., Davies, N. M., & Löbenberg, R.
(2025). Improving Ex Vivo Nasal Mucosa Experimental Design for Drug Permeability Assessments: Correcting Mucosal Thickness Interference and Reevaluating Fluorescein Sodium as an Integrity Marker for Chemically Induced Mucosal Injury. Pharmaceuticals, 18(6), 889.
https://doi.org/10.3390/ph18060889
